← Back to Screener
Artiva Biotherapeutics, Inc. Common Stock (ARTV)
Price$7.46
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)134.23%
Price vs S&P 500 (4W)-31.55%
VGM Score84.84
Market Capitalization$196.00M
All Metrics
Book Value / Share (Quarterly)$3.55
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-49.95%
Cash Flow / Share (Quarterly)$-3.24
Price vs S&P 500 (YTD)73.91%
EPS (TTM)$-3.43
10-Day Avg Trading Volume0.52M
EPS Excl Extra (TTM)$-3.43
EPS (Annual)$-3.43
ROI (Annual)-76.23%
Cash / Share (Quarterly)$3.51
ROA (Last FY)-64.05%
EBITD / Share (TTM)$-3.57
ROE (5Y Avg)-59.61%
Cash Flow / Share (Annual)$-3.23
P/B Ratio2.23x
P/B Ratio (Quarterly)1.81x
Net Income / Employee (Annual)$-806,400
ROA (TTM)-52.38%
EPS Incl Extra (Annual)$-3.43
Current Ratio (Annual)8.61x
Quick Ratio (Quarterly)7.98x
3-Month Avg Trading Volume0.33M
52-Week Price Return286.83%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)780.89x
Asset Turnover (Annual)0.00x
52-Week High$14.53
EPS Excl Extra (Annual)$-3.43
26-Week Price Return150.16%
Quick Ratio (Annual)8.26x
13-Week Price Return45.50%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.16x
Enterprise Value$175.06M
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-26045.02%
Cash / Share (Annual)$4.39
3-Month Return Std Dev135.42%
Net Income / Employee (TTM)$-806,400
ROE (Last FY)-76.26%
EPS Basic Excl Extra (Annual)$-3.43
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.43
Receivables Turnover (Annual)0.49x
ROI (TTM)-60.19%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)258.62%
Year-to-Date Return84.85%
5-Day Price Return0.76%
EPS Normalized (Annual)$-3.43
ROA (5Y Avg)-41.80%
Net Profit Margin (Annual)-26045.02%
Month-to-Date Return-22.56%
EBITD / Share (Annual)$-3.57
Operating Margin (Annual)-26805.58%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-59.59%
EPS Basic Excl Extra (TTM)$-3.43
P/B Ratio (Annual)0.96x
Book Value / Share (Annual)$4.47
Price vs S&P 500 (13W)35.76%
Beta5.52x
Revenue / Share (TTM)$0.00
ROE (TTM)-60.22%
52-Week Low$1.47
mGradeA
vgmGradeA
Show chart for
Earnings Surprise History
Q1 26-0.95est. -0.89
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.25
4.25
4.25
4.25
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ARTVArtiva Biotherapeutics, Inc. Common Stock | — | — | A | $7.46 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Artiva Biotherapeutics develops allogeneic NK cell therapies designed to treat hematologic malignancies and solid tumors. The company's lead program, AlloNK, is an off-the-shelf, cryopreserved NK cell therapy engineered to enhance the antibody-dependent cellular cytotoxicity of monoclonal antibodies. Its pipeline also includes CAR-NK cell candidates (AB201 and AB205) supported by both internal and collaborative funding.